MCID: MLN008
MIFTS: 64

Melanoma

Categories: Cancer diseases, Rare diseases, Skin diseases

Aliases & Classifications for Melanoma

MalaCards integrated aliases for Melanoma:

Name: Melanoma 12 26 38 30 56 6 44 45 15 41 17 74 64
Malignant Melanoma 12 26 15
Cutaneous Melanoma 26 74
Naevocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1909
KEGG 38 H00038
MeSH 45 D008545
NCIt 51 C3224
SNOMED-CT 69 2092003
ICD10 34 D03.9

Summaries for Melanoma

MedlinePlus : 44 Melanoma is the most serious type of skin cancer. Often the first sign of melanoma is a change in the size, shape, color, or feel of a mole. Most melanomas have a black or black-blue area. Melanoma may also appear as a new mole. It may be black, abnormal, or "ugly looking." Thinking of "ABCDE" can help you remember what to watch for: Asymmetry - the shape of one half does not match the other Border - the edges are ragged, blurred or irregular Color - the color is uneven and may include shades of black, brown and tan Diameter - there is a change in size, usually an increase Evolving - the mole has changed over the past few weeks or months Surgery is the first treatment of all stages of melanoma. Other treatments include chemotherapy and radiation, biologic, and targeted therapies. Biologic therapy boosts your body's own ability to fight cancer. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute

MalaCards based summary : Melanoma, also known as malignant melanoma, is related to squamous cell carcinoma, head and neck and lung cancer, and has symptoms including pruritus and exanthema. An important gene associated with Melanoma is FBN1 (Fibrillin 1), and among its related pathways/superpathways are Melanoma and MicroRNAs in cancer. The drugs Erivedge and Intron A have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and t cells.

Disease Ontology : 12 A cell type cancer that has material basis in abnormally proliferating cells derives from melanocytes which are found in skin, the bowel and the eye.

Genetics Home Reference : 26 Melanoma is a type of skin cancer that begins in pigment-producing cells called melanocytes. This cancer typically occurs in areas that are only occasionally sun-exposed; tumors are most commonly found on the back in men and on the legs in women. Melanoma usually occurs on the skin (cutaneous melanoma), but in about 5 percent of cases it develops in melanocytes in other tissues, including the eyes (uveal melanoma) or mucous membranes that line the body's cavities, such as the moist lining of the mouth (mucosal melanoma). Melanoma can develop at any age, but it most frequently occurs in people in their fifties to seventies and is becoming more common in teenagers and young adults.

Novus Biologicals : 57 Melanoma is a malignant tumor that results from uncontrolled growth of pigmented cells, called melanocytes. Several types of melanoma exist, including superficial spreading melanoma, nodular melanoma and lentigo melanoma. Melanoma diagnosis is traditionally supported by the presence of the S-100 protein marker and HMB-45, however research has determined the sensitivity and specificity of three novel antibodies as markers for melanoma: Mitf, Melan-A and tyrosinase.

PubMed Health : 64 About melanoma: We all have moles or other small lumps and bumps that are a different color to the rest of our skin. This is perfectly normal and usually nothing to worry about. It is only rarely skin cancer.Skin cancer comes in different forms. The main types are (malignant) melanoma, basal cell cancer (BCC) and squamous cell cancer (SCC). Basal cell cancer and squamous cell cancer are sometimes grouped together and referred to as non-melanoma skin cancer. Melanoma, which often looks like a very dark mole, is the most widely known type of skin cancer. This is probably because some types are dangerous and can spread very quickly throughout the body.

Wikipedia : 77 Melanoma, also known as malignant melanoma, is a type of cancer that develops from the... more...

Related Diseases for Melanoma

Diseases related to Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1070)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma, head and neck 32.6 CXCL8 MIR205 MIR221 SPRY4-IT1
2 lung cancer 32.1 BANCR CDKN2B-AS1 MIR182 MIR205 MIR221 MIR222
3 neuroblastoma 31.8 CASC15 MIR221 MIR23B MIR34A MIRLET7B
4 breast cancer 31.5 CDKN2B-AS1 CXCL8 MIR182 MIR193B MIR205 MIR221
5 pancreatic cancer 31.2 CDKN2B-AS1 MIR205 MIR221 MIR222 MIR23B MIR34A
6 glioma 31.1 CDKN2B-AS1 MIR221 MIR222 MIR34A PVT1 SPRY4-IT1
7 prostate cancer 31.1 CDKN2B-AS1 MIR182 MIR205 MIR221 MIR222 MIR23B
8 colorectal cancer 31.0 BANCR CDKN2B-AS1 MIR182 MIR221 MIR34A MIRLET7B
9 hepatocellular carcinoma 30.9 BANCR CASC15 CDKN2B-AS1 CXCL8 MIR182 MIR205
10 dermatomyositis 30.9 MIR221 MIR222
11 glioblastoma 30.8 MIR182 MIR221 MIR222 MIR23B MIR34A
12 gastric cancer 30.8 BANCR CASC15 CDKN2B-AS1 MIR221 MIR222 MIR34A
13 thyroid cancer, nonmedullary, 1 30.6 BANCR MIR221 MIR222 MIR34A PVT1
14 leukemia, acute myeloid 30.6 CDKN2B-AS1 MIR182 MIR221 MIR222 MIR23B MIRLET7B
15 bladder cancer 30.6 BANCR CDKN2B-AS1 MIR205 MIR221 MIR222 MIR23B
16 ovarian cancer 30.5 CDKN2B-AS1 MIR182 MIR221 MIR222 PVT1 SPRY4-IT1
17 leukemia, acute lymphoblastic 30.4 MIR221 MIR222 MIR23B MIRLET7B
18 cervical cancer 30.4 CDKN2B-AS1 MIR23B MIRLET7B PVT1 SPRY4-IT1
19 osteogenic sarcoma 30.3 BANCR CDKN2B-AS1 PVT1
20 oral squamous cell carcinoma 30.3 MIR221 MIR23B MIR34A
21 malignant glioma 30.1 CDKN2B-AS1 PVT1 SPRY4-IT1
22 esophageal cancer 30.0 CDKN2B-AS1 CXCL8 MIR205 MIR34A PVT1
23 melanoma, cutaneous malignant 1 12.6
24 melanoma, uveal 12.6
25 ocular melanoma 12.6
26 acral lentiginous melanoma 12.5
27 skin melanoma 12.5
28 melanoma-pancreatic cancer syndrome 12.5
29 melanoma, cutaneous malignant 8 12.5
30 digestive system melanoma 12.4
31 nodular malignant melanoma 12.4
32 melanoma-astrocytoma syndrome 12.4
33 amelanotic melanoma 12.4
34 mucosal melanoma 12.4
35 primary melanoma of the central nervous system 12.4
36 malignant spindle cell melanoma 12.4
37 melanoma-associated retinopathy 12.3
38 melanoma, cutaneous malignant 2 12.3
39 melanoma, cutaneous malignant 3 12.3
40 melanoma, cutaneous malignant 5 12.3
41 melanoma, cutaneous malignant 6 12.3
42 melanoma, cutaneous malignant 9 12.3
43 superficial spreading melanoma 12.3
44 lentigo maligna melanoma 12.3
45 melanoma, cutaneous malignant 4 12.2
46 melanoma, cutaneous malignant 7 12.2
47 melanoma, cutaneous malignant 10 12.2
48 malignant conjunctival melanoma 12.2
49 iris spindle cell melanoma 12.2
50 choroid spindle cell melanoma 12.2

Graphical network of the top 20 diseases related to Melanoma:



Diseases related to Melanoma

Symptoms & Phenotypes for Melanoma

UMLS symptoms related to Melanoma:


pruritus, exanthema

Drugs & Therapeutics for Melanoma

PubMedHealth treatment related to Melanoma: 64

After melanoma is diagnosed, the first step is usually to try to remove it surgically. If it is already advanced or metastatic tumors have developed elsewhere, surgery is combined with other treatments such as medication or radiation.

FDA approved drugs:

(show all 11)
# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Erivedge 19 50 VISMODEGIB Genentech January 2012
2
Intron A 19 50 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
3
Keytruda 19 50 PEMBROLIZUMAB Merck September 2014
4
Mekinist 19 50 TRAMETINIB DIMETHYL SULFOXIDE GlaxoSmithKline May of 2013
5
Odomzo 19 50 SONIDEGIB PHOSPHATE Novartis Jul-15
6
Opdivo 19 50 NIVOLUMAB Bristol-Myers Squibb March 2015/ December 2014, March 2015
7
Proleukin 19 50 ALDESLEUKIN Chiron January 1998
8
Sylatron 19 50 PEGINTERFERON ALFA-2B Merck April 2011
9
Tafinlar 19 50 DABRAFENIB MESYLATE GlaxoSmithKline May 2013
10
Yervoy 19 50 IPILIMUMAB Bristol-Myers Squibb March 2011
11
Zelboraf 19 50 VEMURAFENIB Roche August of 2011

Drugs for Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 728)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 124-94-7 31307
2
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 441203 84093 2767
3
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4342-03-4 5351166
4
Vindesine Approved, Investigational Phase 4 59917-39-4, 53643-48-4 40839
5
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
6
Pembrolizumab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 1374853-91-4
7
Sargramostim Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 123774-72-1, 83869-56-1
8
Trametinib Approved Phase 4,Phase 3,Phase 2,Phase 1 871700-17-3 11707110
9
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
10
Everolimus Approved Phase 4,Phase 2,Phase 1,Not Applicable 159351-69-6 6442177 70789204
11
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
12
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 53123-88-9 46835353 6436030 5284616
13
nivolumab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 946414-94-4
14
Vemurafenib Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 918504-65-1 23252090 42611257
15
Ipilimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 477202-00-9
16
Ceritinib Approved Phase 4,Phase 2,Early Phase 1 1032900-25-6
17
Palbociclib Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 571190-30-2 11431660 5005498 5330286
18
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 284461-73-0 216239 406563
19
Sunitinib Approved, Investigational Phase 4,Phase 2,Phase 1 557795-19-4, 341031-54-7 5329102
20
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 85898-30-2, 110942-02-4
21
Etanercept Approved, Investigational Phase 4 185243-69-0
22
Aminolevulinic acid Approved Phase 4,Phase 2,Not Applicable 106-60-5 137
23
Citalopram Approved Phase 4 59729-33-8 2771
24
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 62-33-9, 60-00-4 6049
25
Pentetic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 67-43-6
26
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 99011-02-6 57469
27
Simvastatin Approved Phase 4 79902-63-9 54454
28
Adalimumab Approved Phase 4 331731-18-1 16219006
29
Dabrafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1195765-45-7 44462760 44516822
30
Pasireotide Approved Phase 4,Phase 3,Phase 2,Phase 1 396091-73-9 9941444
31
Dasatinib Approved, Investigational Phase 4,Phase 2,Phase 1 302962-49-8 3062316
32
Vorinostat Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 149647-78-9 5311
33
Olaparib Approved Phase 4,Phase 1 763113-22-0 23725625
34
Bortezomib Approved, Investigational Phase 4,Phase 2,Phase 1 179324-69-7 387447 93860
35
Ramucirumab Approved, Investigational Phase 4,Phase 2,Phase 1 947687-13-0
36
Crizotinib Approved Phase 4,Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
37
Gefitinib Approved, Investigational Phase 4 184475-35-2 123631
38
Creatine Approved, Investigational, Nutraceutical Phase 4 57-00-1 586
39
Lactitol Investigational Phase 4,Phase 1,Phase 2 585-86-4, 585-88-6 493591
40
Lapatinib Approved March 2007, Investigational Phase 4,Phase 3,Phase 2 388082-78-8, 231277-92-2 208908 9941095
41 Triamcinolone hexacetonide Phase 4,Phase 2,Phase 3,Not Applicable
42 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
43 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
44 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
45 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
46 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
47 Triamcinolone diacetate Phase 4,Phase 2,Phase 3,Not Applicable
48 triamcinolone acetonide Phase 4,Phase 2,Phase 3,Not Applicable
49 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
50 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 2614)
# Name Status NCT ID Phase Drugs
1 TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Unknown status NCT02379000 Phase 4 Triamcinolone Acetonide
2 Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma Unknown status NCT00226473 Phase 4 Cisplatin, Vindesine, Dacarbazine (drugs)
3 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4 Ranibizumab
4 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4 etanercept
5 Post-Operative Drainage Following Lymph Node Dissection Completed NCT00324272 Phase 4 Fibrin Sealant (Tisseel) used in the Experimental Arm.
6 Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream Completed NCT02685592 Phase 4 5-aminolevulinic acid nanoemulsion
7 Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment Completed NCT00352885 Phase 4 Escitalopram;Placebo;IL-2
8 A Study for Lymphocele and Lymphorrhea Control Following Inguinal and Axillary Radical Lymph Node Dissection Completed NCT02476357 Phase 4
9 Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer Completed NCT02287675 Phase 4 Lymphoseek;Sulfur Colloid
10 Effect of Topical Imiquimod on Lentigo Maligna Completed NCT01161888 Phase 4 Imiquimod
11 Surgery Versus Radiosurgery to Treat Metastatic Brain Tumors Completed NCT00075166 Phase 4
12 Assessing the Role of "Statin" Therapy and Perioperative Inflammatory Response in Patients Undergoing Major Orthopedic Surgery Completed NCT00656292 Phase 4 Simvastatin;Placebo
13 An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation Completed NCT01644396 Phase 4
14 Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593) Recruiting NCT03715205 Phase 4 Pembrolizumab
15 Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma Recruiting NCT02451488 Phase 4 GM-CSF
16 Dabrafenib and/or Trametinib Rollover Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
17 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
18 Efficacy of Rapamycin (Sirolimus) in the Treatment of BRBNS, Hereditary or Sporadic Venous Malformation Recruiting NCT03767660 Phase 4 Rapamycin
19 Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies Active, not recruiting NCT02626065 Phase 4 Nivolumab
20 An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma Active, not recruiting NCT01898585 Phase 4 Zelboraf
21 A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. Active, not recruiting NCT02068196 Phase 4 Ipilimumab
22 Flu Vaccine Responses in the Setting of Melanoma Treatment Enrolling by invitation NCT03315975 Phase 4
23 Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma Not yet recruiting NCT02645149 Phase 4 Standard therapy or clinical trial;Matched targeted therapy;Trametinib and / or supportive care
24 Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies Not yet recruiting NCT03673332 Phase 4 immune-checkpoint inhibitors therapies
25 Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1 Not yet recruiting NCT03313544 Phase 4 Nivolumab
26 HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Terminated NCT01683188 Phase 4 vemurafenib + HD IL-2
27 HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Terminated NCT01856023 Phase 4 High Dose Interleukin-2;Ipilimumab
28 Genetically-informed Therapies for Patients With Metastatic Cancer Withdrawn NCT02000739 Phase 4
29 Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients Unknown status NCT01861938 Phase 2, Phase 3
30 Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients Unknown status NCT01729663 Phase 2, Phase 3 interferon alpha 2b
31 Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma Unknown status NCT00002767 Phase 3
32 High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma Unknown status NCT00002763 Phase 3
33 Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma Unknown status NCT00006249 Phase 3
34 Vaccine Therapy in Treating Patients With Primary Stage II Melanoma Unknown status NCT00005052 Phase 3
35 Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver Unknown status NCT00039234 Phase 3 histamine dihydrochloride
36 Vaccine Therapy for Patients With Stage III Melanoma Unknown status NCT00052130 Phase 3
37 Vaccine Therapy for Patients With Stage IV Melanoma Unknown status NCT00052156 Phase 3
38 Treatment Of Radiation Retinopathy Trial Unknown status NCT00811200 Phase 2, Phase 3 ranibizumab;triamcinolone acetonide
39 Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma Unknown status NCT00002455 Phase 3
40 Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC Unknown status NCT00779714 Phase 3 DTIC (dacarbazine);paclitaxel + cisplatin;treosulfan + cytarabine
41 Collaborative Ocular Melanoma Study (COMS) Unknown status NCT00000124 Phase 3
42 Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon Unknown status NCT00226408 Phase 3 Interferon-alpha-2b
43 Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel Unknown status NCT01272609 Phase 3 Timolol + LCP
44 Thymosin-α1 in Cancer-Related Fatigue Unknown status NCT02127268 Phase 3 Thymosin-α1
45 MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma Completed NCT00094653 Phase 3 MDX-010 (anti-CTLA4) monoclonal antibody
46 Nordic Adjuvant IFN Melanoma Trial Completed NCT01259934 Phase 3 Interferon-alpha2b - 1 year;Interferon-alpha2b - 2 years
47 Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma Completed NCT00002882 Phase 3 Cisplatin;Dacarbazine;Vinblastine
48 GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma Completed NCT01245062 Phase 3 GSK1120212;Chemotherapy
49 Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) Completed NCT01974752 Phase 3 75mg selumetinib;placebo;Dacarbazine
50 Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267) Completed NCT00091572 Phase 3 Temozolomide;Dacarbazine

Search NIH Clinical Center for Melanoma

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: melanoma

Genetic Tests for Melanoma

Genetic tests related to Melanoma:

# Genetic test Affiliating Genes
1 Melanoma 30

Anatomical Context for Melanoma

MalaCards organs/tissues related to Melanoma:

42
Skin, Lymph Node, T Cells, Brain, Breast, Eye, Testes

Publications for Melanoma

Articles related to Melanoma:

(show top 50) (show all 22620)
# Title Authors Year
1
Childhood onset atrophic plaque on the chest of a woman with history of acral lentiginous melanoma. ( 30609013 )
2019
2
The Misdiagnosis of Acral Lentiginous Melanoma: Three Case Presentations. ( 30649902 )
2019
3
A pink enlarging plaque on the plantar foot: amelanotic acral lentiginous melanoma. ( 30710904 )
2019
4
Relationship between tumor-associated immune infiltrate and p16 staining over clinicopathological features in acral lentiginous melanoma. ( 30778854 )
2019
5
Does sentinel lymph node status have prognostic significance in patients with acral lentiginous melanoma? ( 30883783 )
2019
6
Lack of association of metastasis-associated lung adenocarcinoma transcript 1 variants with melanoma skin cancer risk. ( 30870271 )
2019
7
Malignant melanoma of the esophagus complicated with poorly differentiated mucinous adenocarcinoma of the stomach: A case report. ( 30855489 )
2019
8
Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma. ( 30792642 )
2019
9
AUSTRALIAN AND NEW ZEALAND STUDY OF PHOTODYNAMIC THERAPY IN CHOROIDAL AMELANOTIC MELANOMA. ( 30908472 )
2019
10
Multiple bone metastases from an amelanotic melanoma of unknown primary origin. ( 30848028 )
2019
11
Amelanotic melanoma. ( 30672881 )
2019
12
Autoimmune Encephalitis Secondary to Melanoma. ( 30743260 )
2019
13
Melanoma Within Basal Cell Carcinoma Nests Discovered During Mohs Micrographic Surgery. ( 30640782 )
2019
14
Extremity nevus count is an independent risk factor for basal cell carcinoma and melanoma, but not squamous cell carcinoma. ( 30713015 )
2019
15
Lesions Mimicking Melanoma at Dermoscopy Confirmed Basal Cell Carcinoma: Evaluation with Reflectance Confocal Microscopy. ( 30404078 )
2019
16
Conditioned media from adipocytes promote proliferation, migration, and invasion in melanoma and colorectal cancer cells. ( 30851074 )
2019
17
Dihydroartemisinin, an antimalarial drug, induces absent in melanoma 2 inflammasome activation and autophagy in human hepatocellular carcinoma HepG2215 cells. ( 30873702 )
2019
18
Integrin α-3 ß-1's central role in breast cancer, melanoma and glioblastoma cell aggregation revealed by antibodies with blocking activity. ( 30810437 )
2019
19
Evaluation of Breast Cancer and Melanoma Metastasis in Syngeneic Mouse Models. ( 30666608 )
2019
20
Malignant melanoma on a thermal burn scar. ( 30703864 )
2019
21
Clear cell sarcoma of the soft palate mimicking unclassified melanoma. ( 30837084 )
2019
22
Nivolumab-induced colitis in a patient with malignant melanoma: A case report and immunological analysis. ( 30908699 )
2019
23
Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma. ( 30666357 )
2019
24
A case of Cowden syndrome associated with melanoma: the role of the dermatologist. ( 30717572 )
2019
25
Complete response of metastatic melanoma in a patient with Crohn's disease simultaneously receiving anti-α4β7 and anti-PD1 antibodies. ( 30612589 )
2019
26
Combined immune therapy grade IV dermatitis in metastatic melanoma. ( 30809956 )
2019
27
Juvenile dermatomyositis associated with anti-melanoma differentiation-associated gene 5 antibody positivity without complications of interstitial lung disease during the clinical course: A case report. ( 30869164 )
2019
28
Liver dysfunction in anti-melanoma differentiation-associated gene 5 antibody-positive patients with dermatomyositis. ( 30790016 )
2019
29
Survival and glycemic control in patients with coexisting melanoma and diabetes mellitus. ( 30906566 )
2019
30
A case of nivolumab-induced acute-onset type 1 diabetes mellitus in melanoma. ( 30853818 )
2019
31
Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergy with anti-PD-1 in melanoma. ( 30718426 )
2019
32
Vemurafenib and cobimetinib combination therapy for BRAFV600E-mutated melanoma favors posterior reversible encephalopathy syndrome. ( 30911762 )
2019
33
Utilizing photosensitizing and radiosensitizing properties of TiO2-based mitoxantrone imprinted nanopolymer in killing fibrosarcoma and melanoma cells. ( 30738223 )
2019
34
Antitumor response to microscopic melanoma in the gastric mucosa mimicking ipilimumab-induced gastritis. ( 30744698 )
2019
35
Synthetic lethality of a cell-penetrating anti-RAD51 antibody in PTEN-deficient melanoma and glioma cells. ( 30863489 )
2019
36
Primary large anorectal melanoma presenting as intermittent rectal bleeding and mimicking a hemorrhoid. ( 30710702 )
2019
37
Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma. ( 30791949 )
2019
38
A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma. ( 30836329 )
2019
39
Targeting intermittent hypoxia downstream pathways for biomarker discovery and new treatment perspectives in cutaneous melanoma. ( 30769330 )
2019
40
LRIG1 acts as a critical regulator of melanoma cell invasion, migration, and vasculogenic mimicry upon hypoxia by regulating EGFR/ERK-triggered epithelial-mesenchymal transition. ( 30487162 )
2019
41
Association between inflammatory bowel disease and uveal melanoma: case report of two young adults and a literature review. ( 30455614 )
2019
42
Immunobiochemical Reconstruction of Influenza Lung Infection-Melanoma Skin Cancer Interactions. ( 30745900 )
2019
43
Ileocaecal intussusception due to melanoma from an unknown primary. ( 30675982 )
2019
44
Management of intussusception in patients with melanoma. ( 30734297 )
2019
45
Verrucous melanoma masquerading as a seborrheic keratosis. ( 30865414 )
2019
46
Nine percent of biopsy proven lentigo maligna are reclassified as lentigo maligna melanoma after surgery. ( 30716164 )
2019
47
Histologic predictors of invasion in partially biopsied lentigo maligna melanoma. ( 30879481 )
2019
48
A rare pitfall in the molecular interpretation of BRAF V600E status in melanoma in the setting of BRAF V600E-mutated chronic lymphocytic leukemia/small lymphocytic lymphoma. ( 30734348 )
2019
49
Li-Fraumeni syndrome presenting as cutaneous melanoma in a child: case report and review of literature. ( 30653764 )
2019
50
Letter to editor: Surgical-site infection following lymph node excision indicates susceptibility for lymphedema: A retrospective cohort study of malignant melanoma patients. ( 30733079 )
2019

Variations for Melanoma

ClinVar genetic disease variations for Melanoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 FBN1 NM_000138.4(FBN1): c.5788+5G> A single nucleotide variant Pathogenic rs193922219 GRCh37 Chromosome 15, 48738898: 48738898
2 FBN1 NM_000138.4(FBN1): c.5788+5G> A single nucleotide variant Pathogenic rs193922219 GRCh38 Chromosome 15, 48446701: 48446701
3 CDKN2A NM_000077.4(CDKN2A): c.197A> C (p.His66Pro) single nucleotide variant Uncertain significance rs756750256 GRCh38 Chromosome 9, 21971162: 21971162
4 CDKN2A NM_000077.4(CDKN2A): c.197A> C (p.His66Pro) single nucleotide variant Uncertain significance rs756750256 GRCh37 Chromosome 9, 21971161: 21971161
5 BRCA2 NM_000059.3(BRCA2): c.2063A> G (p.Tyr688Cys) single nucleotide variant Uncertain significance rs28897713 GRCh38 Chromosome 13, 32336418: 32336418
6 BRCA2 NM_000059.3(BRCA2): c.2063A> G (p.Tyr688Cys) single nucleotide variant Uncertain significance rs28897713 GRCh37 Chromosome 13, 32910555: 32910555

Cosmic variations for Melanoma:

9 (show top 50) (show all 547)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6976263 ZFHX3 skin,mucosal,malignant melanoma,NS c.1064C>T p.A355V 16:72959082-72959082 0
2 COSM1703787 WT1 skin,leg,malignant melanoma,NS c.1169G>A p.R390Q 11:32392031-32392031 0
3 COSM7408648 TSC1 skin,mucosal,malignant melanoma,NS c.2281T>C p.Y761H 9:132902715-132902715 0
4 COSM7408647 TSC1 skin,mucosal,malignant melanoma,NS c.2102A>G p.Q701R 9:132903757-132903757 0
5 COSM7408642 TSC1 skin,mucosal,malignant melanoma,NS c.587C>A p.P196H 9:132921895-132921895 0
6 COSM6912060 TSC1 skin,mucosal,malignant melanoma,NS c.323C>T p.S108F 9:132925627-132925627 0
7 COSM7408651 TSC1 skin,mucosal,malignant melanoma,NS c.1598C>A p.P533H 9:132905980-132905980 0
8 COSM7408649 TSC1 skin,mucosal,malignant melanoma,NS c.2974A>G p.R992G 9:132897185-132897185 0
9 COSM7408644 TSC1 skin,mucosal,malignant melanoma,NS c.2541C>A p.F847L 9:132900799-132900799 0
10 COSM7408646 TSC1 skin,mucosal,malignant melanoma,NS c.1375C>G p.L459V 9:132906794-132906794 0
11 COSM7408652 TSC1 skin,mucosal,malignant melanoma,NS c.2518T>A p.S840T 9:132900822-132900822 0
12 COSM7408650 TSC1 skin,mucosal,malignant melanoma,NS c.322T>C p.S108P 9:132925628-132925628 0
13 COSM107494 TRRAP skin,leg,malignant melanoma,NS c.2165C>T p.S722F 7:98912179-98912179 0
14 COSM6939354 TRAF2 skin,mucosal,malignant melanoma,NS c.923G>A p.R308Q 9:136920478-136920478 0
15 COSM44026 TP53 skin,NS,malignant melanoma,superficial spreading c.559G>A p.G187S 17:7675053-7675053 0
16 COSM10662 TP53 skin,mucosal,malignant melanoma,NS c.743G>A p.R248Q 17:7674220-7674220 0
17 COSM10718 TP53 skin,mucosal,malignant melanoma,NS c.524G>T p.R175L 17:7675088-7675088 0
18 COSM10867 TP53 skin,NS,malignant melanoma,nodular c.797G>A p.G266E 17:7673823-7673823 0
19 COSM6913 TP53 skin,mucosal,malignant melanoma,NS c.783-1G>T p.? 17:7673838-7673838 0
20 COSM10794 TP53 skin,mucosal,malignant melanoma,NS c.796G>A p.G266R 17:7673824-7673824 0
21 COSM46043 TP53 skin,mucosal,malignant melanoma,NS c.375+2T>G p.? 17:7675992-7675992 0
22 COSM10704 TP53 skin,mucosal,malignant melanoma,NS c.844C>T p.R282W 17:7673776-7673776 0
23 COSM43690 TP53 skin,NS,malignant melanoma,superficial spreading c.592G>A p.E198K 17:7674939-7674939 0
24 COSM10656 TP53 skin,NS,malignant melanoma,superficial spreading c.742C>T p.R248W 17:7674221-7674221 0
25 COSM10863 TP53 skin,back,malignant melanoma,NS c.833C>T p.P278L 17:7673787-7673787 0
26 COSM108917 TMEM132B skin,leg,malignant melanoma,NS c.2465G>A p.G822E 12:125653938-125653938 0
27 COSM131816 TIE1 skin,leg,malignant melanoma,NS c.292G>A p.D98N 1:43305084-43305084 0
28 COSM6913900 TET2 skin,mucosal,malignant melanoma,NS c.3352A>G p.N1118D 4:105237294-105237294 0
29 COSM6966846 STAG2 skin,mucosal,malignant melanoma,NS c.2927A>T p.D976V 23:124083423-124083423 0
30 COSM6922321 SMARCA4 skin,mucosal,malignant melanoma,NS c.797C>T p.S266L 19:10986941-10986941 0
31 COSM5342615 SMAD3 skin,leg,malignant melanoma,NS c.1072C>T p.Q358* 15:67187427-67187427 0
32 COSM110696 SF3B1 skin,mucosal,malignant melanoma,NS c.1873C>T p.R625C 2:197402760-197402760 0
33 COSM255276 SF3B1 skin,mucosal,malignant melanoma,NS c.1874G>A p.R625H 2:197402759-197402759 0
34 COSM110695 SF3B1 skin,mucosal,malignant melanoma,NS c.1874G>T p.R625L 2:197402759-197402759 0
35 COSM6962716 SF3B1 skin,mucosal,malignant melanoma,NS c.2890A>G p.T964A 2:197400263-197400263 0
36 COSM5610575 RUNX1T1 skin,back,malignant melanoma,NS c.206C>T p.S69F 8:92014730-92014730 0
37 COSM5610538 RPTOR skin,back,malignant melanoma,NS c.484G>A p.G162R 17:80707976-80707976 0
38 COSM6957170 ROS1 skin,mucosal,malignant melanoma,NS c.822A>C p.E274D 6:117396222-117396222 0
39 COSM131810 ROR2 skin,back,malignant melanoma,NS c.1172T>C p.V391A 9:91730921-91730921 0
40 COSM6922951 RB1 skin,mucosal,malignant melanoma,NS c.1361A>G p.Y454C 13:48379622-48379622 0
41 COSM6939092 RB1 skin,mucosal,malignant melanoma,NS c.2486C>T p.S829L 13:48465365-48465365 0
42 COSM6934533 RB1 skin,mucosal,malignant melanoma,NS c.1328C>A p.S443* 13:48377030-48377030 0
43 COSM6922949 RB1 skin,mucosal,malignant melanoma,NS c.1340A>T p.K447I 13:48379601-48379601 0
44 COSM125734 RAC1 skin,NS,malignant melanoma,nodular c.85C>T p.P29S 7:6387261-6387261 0
45 COSM5038556 RAC1 skin,mucosal,malignant melanoma,NS c.276T>A p.N92K 7:6400176-6400176 0
46 COSM6939356 RAB35 skin,mucosal,malignant melanoma,NS c.494C>T p.T165M 12:120097357-120097357 0
47 COSM6983124 RAB35 skin,mucosal,malignant melanoma,NS c.477+1G>T p.? 12:120098810-120098810 0
48 COSM142711 PTPRT skin,back,malignant melanoma,NS c.4372G>A p.E1458K 20:42080899-42080899 0
49 COSM6909358 PTPRT skin,mucosal,malignant melanoma,NS c.1852G>A p.G618R 20:42350641-42350641 0
50 COSM142709 PTPRT skin,leg,malignant melanoma,NS c.3331G>A p.G1111R 20:42106911-42106911 0

Copy number variations for Melanoma from CNVD:

7 (show top 50) (show all 1973)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13791 1 1 46500000 Insertion Melanoma
2 13897 1 1007060 1041599 Amplification C1orf159 Melanoma
3 14968 1 111600000 148000000 Deletion Melanoma
4 15008 1 111800000 116100000 Gain NRAS Melanoma
5 15387 1 115048600 115061038 Gain NRAS Melanoma
6 18715 1 147200000 149200000 Ampfication SETDB1 Melanoma
7 20086 1 15300000 247249719 Insertion Melanoma
8 21281 7 92072170 92303813 Gain CDK6 Malignant melanoma
9 24543 1 182188599 196365692 Amplification ASPM Melanoma
10 24544 1 182188599 196365692 Amplification ATP6V1G3 Melanoma
11 24545 1 182188599 196365692 Amplification B3GALT2 Melanoma
12 24546 1 182188599 196365692 Amplification C1orf27 Melanoma
13 24547 1 182188599 196365692 Amplification C1orf53 Melanoma
14 24548 1 182188599 196365692 Amplification C1orf99 Melanoma
15 24549 1 182188599 196365692 Amplification CDC73 Melanoma
16 24550 1 182188599 196365692 Amplification CFH Melanoma
17 24551 1 182188599 196365692 Amplification CFHR1 Melanoma
18 24552 1 182188599 196365692 Amplification CFHR2 Melanoma
19 24553 1 182188599 196365692 Amplification CFHR3 Melanoma
20 24554 1 182188599 196365692 Amplification CFHR4 Melanoma
21 24555 1 182188599 196365692 Amplification CFHR5 Melanoma
22 24556 1 182188599 196365692 Amplification CRB1 Melanoma
23 24557 1 182188599 196365692 Amplification DENND1B Melanoma
24 24558 1 182188599 196365692 Amplification F13B Melanoma
25 24559 1 182188599 196365692 Amplification FAM5C Melanoma
26 24560 1 182188599 196365692 Amplification GLRX2 Melanoma
27 24561 1 182188599 196365692 Amplification HMCN1 Melanoma
28 24562 1 182188599 196365692 Amplification KCNT2 Melanoma
29 24563 1 182188599 196365692 Amplification LHX9 Melanoma
30 24564 1 182188599 196365692 Amplification NEK7 Melanoma
31 24565 1 182188599 196365692 Amplification OCLM Melanoma
32 24566 1 182188599 196365692 Amplification PDC Melanoma
33 24567 1 182188599 196365692 Amplification PLA2G4A Melanoma
34 24568 1 182188599 196365692 Amplification PRG4 Melanoma
35 24569 1 182188599 196365692 Amplification PTGS2 Melanoma
36 24570 1 182188599 196365692 Amplification PTPRC Melanoma
37 24571 1 182188599 196365692 Amplification RGS1 Melanoma
38 24572 1 182188599 196365692 Amplification RGS13 Melanoma
39 24573 1 182188599 196365692 Amplification RGS18 Melanoma
40 24574 1 182188599 196365692 Amplification RGS2 Melanoma
41 24575 1 182188599 196365692 Amplification RGS21 Melanoma
42 24576 1 182188599 196365692 Amplification TPR Melanoma
43 24577 1 182188599 196365692 Amplification TROVE2 Melanoma
44 24578 1 182188599 196365692 Amplification UCHL5 Melanoma
45 24579 1 182188599 196365692 Amplification ZBTB41 Melanoma
46 26238 1 198304656 198310281 Deletion Melanoma
47 29172 1 228366540 228914590 LOH Melanoma
48 29295 1 2300000 46500000 Insertion Melanoma
49 29296 1 2300000 46500000 Insertion Melanoma
50 30306 1 241700000 247249719 Insertion Melanoma

Expression for Melanoma

Search GEO for disease gene expression data for Melanoma.

Pathways for Melanoma

Pathways related to Melanoma according to KEGG:

38
# Name Kegg Source Accession
1 Melanoma hsa05218

Pathways related to Melanoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.64 MIR193B MIR205 MIR221 MIR222 MIR23B MIR34A
2 10.83 MIR221 MIR222 MIR23B

GO Terms for Melanoma

Cellular components related to Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 CCL27 CXCL8 FBN1 MIR182 MIR205 MIR221
2 micro-ribonucleoprotein complex GO:0035068 9.23 MIR182 MIR193B MIR205 MIR221 MIR222 MIR23B

Biological processes related to Melanoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.88 CDKN2B-AS1 MIR182 MIR23B MIR34A
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.83 MIR221 MIR222 MIR23B MIRLET7B
3 negative regulation of angiogenesis GO:0016525 9.72 MIR222 MIR34A STAT1
4 miRNA mediated inhibition of translation GO:0035278 9.69 MIR182 MIR221 MIR222
5 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.57 MIR23B MIRLET7B
6 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.56 MIR182 MIR34A
7 negative regulation of cytokine production involved in inflammatory response GO:1900016 9.54 MIR221 MIR222
8 negative regulation of sprouting angiogenesis GO:1903671 9.54 MIR221 MIR23B MIR34A
9 positive regulation of erythrocyte differentiation GO:0045648 9.5 MIR221 MIR222 STAT1
10 negative regulation by host of viral genome replication GO:0044828 9.49 MIR221 MIR222
11 positive regulation of axon regeneration GO:0048680 9.48 MIR221 MIR222
12 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.46 MIR221 MIR222
13 negative regulation of cell adhesion molecule production GO:0060354 9.43 MIR221 MIR222
14 negative regulation of TRAIL-activated apoptotic signaling pathway GO:1903122 9.4 MIR221 MIR222
15 negative regulation of hematopoietic stem cell proliferation GO:1902034 9.26 MIR221 MIR222
16 gene silencing by miRNA GO:0035195 9.23 MIR182 MIR193B MIR205 MIR221 MIR222 MIR23B
17 positive regulation of Schwann cell migration GO:1900149 9.16 MIR221 MIR222
18 positive regulation of Schwann cell proliferation involved in axon regeneration GO:1905046 8.96 MIR221 MIR222

Molecular functions related to Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.17 MIR182 MIR193B MIR221 MIR222 MIR23B MIR34A

Sources for Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....